Total
0
Shares
Prescient Therapeutics (ASX:PTX) - CEO & Managing Director, Steven Yatomi-Clarke - The Market Herald
CEO & Managing Director, Steven Yatomi
Source: The Australian
  • Two of Prescient Therapeutics' (PTX) assets have been handpicked for a COVID-19 antiviral testing program
  • The trial, run by the renowned Doherty Institute, will take place in two phases — encompassing a test-tube experiment and a study in small animals
  • The institute's study will assess the effectiveness of a wide variety of formulations against COVID-19
  • Significantly, both of Prescient's assets were classed as group one candidates — meaning they have "the highest or strong likelihood of antiviral efficacy"
  • To support the trial, Prescient will provide $70,000 in funding, while any intellectual property from the study will be protected by patents
  • Initial results from the program are expected around September and October
  • Prescient shares have jumped 15.5 per cent today, trading for 6.7 cents per share

Two of Prescient Therapeutics' (PTX) assets have been handpicked for a COVID-19 antiviral testing program.

The trial, run by the renowned Doherty Institute, will take place in two phases — encompassing a test-tube experiment and a study in small animals.

The institute's study will assess the effectiveness of a wide variety of formulations against COVID-19. Significantly, both of Prescient's assets were classed as group one candidates — meaning they have "the highest or strong likelihood of antiviral efficacy."

The Doherty Institute, formed from a joint venture between the University of Melbourne and the Royal Melbourne Hospital, specialises in "the prevention, treatment and cure of infectious diseases." Interestingly, the institute was the first outside of China to develop the SARS-CoV-2 strain in cell culture and bring it to other laboratories in the fight against COVID-19.

“While we remain totally focused on advancing our promising anti-cancer clinical pipeline, we are delighted that two of our assets have been selected for this important national effort by some of the world’s leading medical researchers to help address this urgent global health emergency,” Prescient CEO Steven Yatomi-Clarke stated.

To support the trial, Prescient will provide $70,000 in funding, while any intellectual property from the study will be protected by patents. Initial results from the program are expected around September and October.

Prescient shares have jumped 15.5 per cent today, trading for 6.7 cents per share at market close.


Subscribe


PTX by the numbers
More From The Market Herald
Getting enough sleep? Mental wellness app spikes 117 per cent with new signing

" Medibio’s (ASX:MED) sleep software and study affected by COVID-19

Meditech company Medibio (MED) has revealed it’s facing some setbacks due to the ongoing coronavirus pandemic.
Skin Elements (ASX:SKN) - Executive Chairman, Peter Malone - The Market Herald

" Skin Elements (ASX:SKN) enters $2.4M agreement with Prudential Consultants

Skin Elements (SKN) has entered a binding distribution agreement with Prudential Consultants to distribute its Invisi Shield Organics hand sanitiser in Australia.
Could MGC Pharmaceuticals (ASX:MXC) hold the treatment for COVID-19?

" Could MGC Pharmaceuticals (ASX:MXC) hold the treatment for COVID-19?

MGC Pharmaceuticals (MXC) phytocannabinoid-derived medical spray, ArtemiC, could be used as an effective treatment for COVID-19.
G Medical Innovations (ASX:GMV) - CEO, Dr Yacov Geva - The Market Herald

" G Medical Innovations (ASX:GMV) receives firm commitments for $5M placement

Telehealth company G Medical Innovations (GMV) has received firm commitments to undertake a $5 million placement.